STTK
Shattuck Labs, Inc. [STTK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
STTK Stock Summary
Top 10 Correlated Stocks
STTK
In the News
STTK Financial details
Company Rating
-
Market Cap
443.41M
Income
-86.36M
Revenue
1.66M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
75
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.51
Forward P/E
-
PEG
3.14
P/S
349.72
P/B
3.72
P/C
-
P/FCF
-5.37
Quick Ratio
7.19
Current Ratio
8.04
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.03
EPS next Y
-
EPS next Q
-
EPS this Y
-13.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
29.17%
Revenue last 5Y
-30.04%
Revenue Q/Q
4.08%
EPS Q/Q
-36.92%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-71%
ROE
-64%
ROC
-0.85%
Gross Margin
100%
Oper. Margin
-7448%
Profit Margin
-6993%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.33-11.11
52W High
-92.13%
52W Low
-13.38%
RSI
32
Rel Volume
0.41
Avg Volume
330.26K
Volume
133.79K
Perf Week
-27.21%
Perf Month
-32.85%
Perf Quarter
-38.13%
Perf Half Y
-77.62%
-
-
-
-
Beta
2.126
-
-
Volatility
0.1%, 0.2%
Prev Close
-8.83%
Price
0.8662
Change
-17.5%
Company Profile
- Volume Average 330.26K
- Market Capitalization 443.41M
- Employee 75
- CEO Dr. Taylor H. Schreiber M.D., Ph.D.
- Headquarters Austin,TX,US
- IPO Date 2020-10-09
-
Website
https://www.shattucklabs.com 
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
